Cargando…
Mutation testing in melanoma families: INK4A, CDK4 and INK4D
The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363010/ https://www.ncbi.nlm.nih.gov/pubmed/10390011 http://dx.doi.org/10.1038/sj.bjc.6690354 |
_version_ | 1782153597279010816 |
---|---|
author | Newton Bishop, J A Harland, M Bennett, D C Bataille, V Goldstein, A M Tucker, M A Ponder, B A J Cuzick, J Selby, P Bishop, D T |
author_facet | Newton Bishop, J A Harland, M Bennett, D C Bataille, V Goldstein, A M Tucker, M A Ponder, B A J Cuzick, J Selby, P Bishop, D T |
author_sort | Newton Bishop, J A |
collection | PubMed |
description | The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of the INK4A and CDK4 genes in 42 UK families. A total of nine families were identified with INK4A mutations and none with CDK4 exon 2 mutations. These mutations were in 8/22 (35%) families with three or more cases of melanoma and 1/20 (5%) families with only two cases. In one of these nine families a novel single base pair substitution was identified, Gly67Arg. In an attempt to identify another melanoma susceptibility gene, a member of the INK4 family, the p19 INK4D gene has been studied. The p19 gene was sequenced in DNA from the 42 UK families and six additional US families. No mutations were identified. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2363010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23630102009-09-10 Mutation testing in melanoma families: INK4A, CDK4 and INK4D Newton Bishop, J A Harland, M Bennett, D C Bataille, V Goldstein, A M Tucker, M A Ponder, B A J Cuzick, J Selby, P Bishop, D T Br J Cancer Regular Article The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of the INK4A and CDK4 genes in 42 UK families. A total of nine families were identified with INK4A mutations and none with CDK4 exon 2 mutations. These mutations were in 8/22 (35%) families with three or more cases of melanoma and 1/20 (5%) families with only two cases. In one of these nine families a novel single base pair substitution was identified, Gly67Arg. In an attempt to identify another melanoma susceptibility gene, a member of the INK4 family, the p19 INK4D gene has been studied. The p19 gene was sequenced in DNA from the 42 UK families and six additional US families. No mutations were identified. © 1999 Cancer Research Campaign Nature Publishing Group 1999-04 /pmc/articles/PMC2363010/ /pubmed/10390011 http://dx.doi.org/10.1038/sj.bjc.6690354 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Newton Bishop, J A Harland, M Bennett, D C Bataille, V Goldstein, A M Tucker, M A Ponder, B A J Cuzick, J Selby, P Bishop, D T Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title_full | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title_fullStr | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title_full_unstemmed | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title_short | Mutation testing in melanoma families: INK4A, CDK4 and INK4D |
title_sort | mutation testing in melanoma families: ink4a, cdk4 and ink4d |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363010/ https://www.ncbi.nlm.nih.gov/pubmed/10390011 http://dx.doi.org/10.1038/sj.bjc.6690354 |
work_keys_str_mv | AT newtonbishopja mutationtestinginmelanomafamiliesink4acdk4andink4d AT harlandm mutationtestinginmelanomafamiliesink4acdk4andink4d AT bennettdc mutationtestinginmelanomafamiliesink4acdk4andink4d AT bataillev mutationtestinginmelanomafamiliesink4acdk4andink4d AT goldsteinam mutationtestinginmelanomafamiliesink4acdk4andink4d AT tuckerma mutationtestinginmelanomafamiliesink4acdk4andink4d AT ponderbaj mutationtestinginmelanomafamiliesink4acdk4andink4d AT cuzickj mutationtestinginmelanomafamiliesink4acdk4andink4d AT selbyp mutationtestinginmelanomafamiliesink4acdk4andink4d AT bishopdt mutationtestinginmelanomafamiliesink4acdk4andink4d |